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Abbreviation Full Term 
VTE Venous thromboembolism 
UFH Unfractionated heparin 
HIT Heparin induced thrombocytopenia 
DTI Direct thrombin inhibitor 
tPA Tissue plasminogen activator 
ECHO Echocardiogram 
aPTT Activated partial thromboplastin time 
IVC Inferior vena cava 
PF4 Platelet factor 4 
PE Pulmonary embolism 
 19 
Abstract 20 
 Venous thromboembolism (VTE) has increasing significance in hospitalized pediatric 21 
patients.  Patients that have life or limb threatening thrombotic events require thrombolysis in 22 
addition to anticoagulation (AC). In patients who show signs of heparin resistance or heparin 23 
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present a child in whom bivalirudin was used for systemic AC during catheter directed thrombolysis 25 
along with tissue plasminogen activator (tPA, Alteplase®) for the treatment of a near-occlusive organ 26 
threatening thrombus.  We also review the currently available literature on the use of combination 27 
therapy of an intravenous direct thrombin inhibitor with alteplase. 28 
Introduction 29 
 The incidence of pediatric venous thromboembolism (VTE) has increased over the last 30 
decade1  and patients are prescribed anticoagulation therapy to prevent extension and recurrence.2 31 
Unfractionated heparin (UFH), low-molecular-weight heparins, and vitamin K antagonists are the 32 
mainstay of anticoagulation in children.1–3 In patients with heparin resistance, difficulty in achieving 33 
therapeutic heparin levels or in those who develop heparin induced thrombocytopenia (HIT), 34 
alternative options need to be identified. Bivalirudin, a direct thrombin inhibitor (DTI), that inhibits 35 
circulating and clot-associated thrombin, is an effective anticoagulant in children.3,4 However, 36 
patients who develop limb or organ threatening thromboses may require additional thrombolytic 37 
treatment. We present a child in whom bivalirudin was used for systemic anticoagulation during 38 
catheter-directed thrombolysis using tissue plasminogen activator (tPA, Alteplase®) and review the 39 
current literature on the use of combination therapy of an intravenous DTI and alteplase. 40 
Case Report 41 
 A 2-year-old male with Down syndrome and artificial heart valves on warfarin presented 42 
with shock. An echocardiogram (ECHO) showed moderate right ventricular dilation with increased 43 
pressures, but no signs of thrombus or vegetation. Blood work revealed an international normalized 44 
ratio of 7, and he received Vitamin K and fresh frozen plasma.  Warfarin was discontinued, and he 45 
was started on UFH [goal activated partial thromboplastin time (aPTT) of 48-78 seconds].   46 
 Five weeks later, a repeat ECHO revealed an echogenic density in the hepatic inferior vena 47 
cava (IVC) with near complete occlusion and extension of the thrombus into the right renal vein. 48 
Given the development of an organ threatening thrombus while on high doses of UFH (>50 49 
units/kg/hr) there was suspicion for development of HIT.  Bivalirudin was started at 0.3 mg/kg/hr 50 
with a goal aPTT of 1.5 – 2 times his baseline (30 seconds). After 12 hours, catheter-directed 51 
alteplase was initiated at 0.03 mg/kg/hr and bivalirudin dose was reduced by 50% with a goal aPTT 52 
of 45-60 seconds. ECHO after 24 hours of catheter-directed alteplase showed worsening of 53 
thrombus, and alteplase was increased to 0.06 mg/kg/hr for an additional 48 hours; bivalirudin was 54 
increased to a maximum of 0.3 mg/kg/hr to maintain a goal aPTT of 45-60 seconds. After 48 hours, 55 
ECHO showed decreasing thrombus with improved IVC flow. Throughout treatment the patient’s 56 
laboratory parameters including fibrinogen, plasminogen, and platelet counts were monitored and 57 
remained within normal limits and there were no bleeding complications. Platelet factor 4 (PF4) 58 
screen was negative indicating no evidence of HIT. With thrombus stabilization, alteplase was 59 
discontinued and bivalirudin was titrated to maintain a goal aPTT of 45 – 60 seconds. Unfortunately, 60 
the patient passed away 4 weeks later due to persistent candidal sepsis. 61 
Discussion 62 
The American College of Chest Physicians recommends thrombolysis in children with organ or limb 63 
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prevent new clot formation as clot lysis releases thrombin during thrombolysis.2 In patients with 65 
heparin resistance or HIT, choosing an alternative anticoagulant becomes imperative. DTIs have 66 
been used an alternative to UFH in patients with HIT. Bivalirudin is a commercially available DTI that 67 
has been used in pediatric patients with VTE and cardiac catheterization.3,4 Its use during 68 
thrombolysis has been limited, although there are few reports of use of DTI with thrombolytic 69 
therapy in adult patients (Table 1). 70 
Badreldin et al.6 reported a case of bivalirudin and alteplase in an adult male with HIT and recurrent 71 
DVTs with new unstable pulmonary embolism (PE). Martinez and Burnett7 reported an adult female 72 
with extensive thrombosis of the bilateral lower extremities and IVC dilatation who developed HIT. 73 
Lausin et al.8 used systemic bivalirudin during catheter-directed thrombolysis with alteplase for an 74 
adult male patient with PE. Patients were prescribed DTI with 50% reduction in dosing during 75 
thrombolytic therapy and with variable target aPTTs. All had improvement in thrombus size and no 76 
bleeding events during thrombolytic therapy.  77 
There is a strong need for alternative options for systemic anticoagulation in critically ill patients 78 
requiring thrombolytic therapy when heparin is contraindicated. It is unclear why our patient was 79 
refractory to heparin, as his PF4 screen was negative and antithrombin level was only mildly low at 80 
67%; although likely multifactorial due to critically ill condition. In children, the recommended dose 81 
of tPA is highly variable. Recommendations vary with some using a low dose (0.01-0.06 mg/kg/hr) to 82 
high dose (0.1-0.5 mg /kg/hr).2 Our patient was successfully treated with alteplase at 0.03 – 0.06 83 
mg/kg/hr while receiving systemic anticoagulation with bivalirudin at a 50% dose reduction. In our 84 
review, this is the first pediatric patient where combination therapy (DTI and alteplase) has been 85 
reported. 86 
Conflict of Interest Statement 87 
Authors K. Regling, M. Callaghan, and M. Rajpurkar have no disclosures to acknowledge. 88 
Acknowledgements 89 
Dr. Katherine Regling collected and reviewed the data and wrote the manuscript under the 90 
mentorship of Dr. Michael U. Callaghan and Dr. Madhvi Rajpurkar. 91 
References 92 
1.  Raffini L, Huang Y-S, Witmer C, Feudtner C. Dramatic Increase in Venous Thromboembolism 93 
in Children’s Hospitals in the United States From 2001 to 2007. Pediatrics. 2009;124(4):1001-1008. 94 
doi:10.1542/peds.2009-0768 95 
2.  Tarango C, Manco-Johnson MJ. Pediatric Thrombolysis: A Practical Approach. Front Pediatr. 96 
2017;5(December):1-7. doi:10.3389/fped.2017.00260 97 
3.  Young G. Anticoagulation Therapies in Children. Pediatr Clin North Am. 2017;64(6):1257-98 
1269. doi:10.1016/j.pcl.2017.08.004 99 
4.  Forbes TJ, Hijazi ZM, Young G, et al. Pediatric catheterization laboratory anticoagulation with 100 




This article is protected by copyright. All rights reserved. 
 
5.  Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and 102 
children: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest 103 
physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 SUPPL.):e737S-e801S. 104 
doi:10.1378/chest.11-2308 105 
6.  Badreldin HA, Rimsans J, Connors JM, Wiviott SD. Use of systemic bivalirudin with catheter-106 
directed thrombolysis in a patient with heparin-induced thrombocytopenia: A case report. Catheter 107 
Cardiovasc Interv. 2018;91(3):E17-E20. doi:10.1002/ccd.27368 108 
7.  Martinez LA, Burnett AE. Catheter-directed thrombolysis with alteplase and bivalirudin in a 109 
patient with heparin-induced thrombocytopenia. Am J Heal Pharm. 2015;72(9):707-710. 110 
doi:10.2146/ajhp140474 111 
8.  Lausin A, Fink J, Sutter C, Russo N. 12-267 - Catheter-Directed Thrombolysis with Alteplase 112 
and Bivalirudin for Treatment of Pulmonary Embolism. 113 
9.  Bethea BT, Elliot JW, Richardson JB, Ahmed MI. Treatment of pulmonary embolism with 114 
argatroban and ultrasound-assisted catheter-directed thrombolysis with alteplase in a patient with 115 
heparin-induced thrombocytopenia. Am J Heal Pharm. 2017;74(15):1153-1157. 116 
doi:10.2146/ajhp160368 117 
10.  Sin JH, Yen DC. Catheter-Directed Thrombolysis with Direct Intra-Catheter Administration of 118 
Argatroban and Alteplase for Extensive Deep Vein Thrombosis in a Patient with Heparin-Induced 119 
Thrombocytopenia. 2017:36-38. 120 
11.  Sharifi M, Bay C, Nowroozi S, Bentz S, Valeros G, Memari S. Catheter-directed thrombolysis 121 
with argatroban and tPA for massive iliac and femoropopliteal vein thrombosis. Cardiovasc Intervent 122 
Radiol. 2013;36(6):1586-1590. doi:10.1007/s00270-013-0569-3 123 
12.  Maldonado A. Argatroban and catheter-directed thrombolysis with alteplase for limb- and 124 
graft-threatening thromboses in a patient with a history of HIT. Am J Hematol. 2009;84(4):251-253. 125 
doi:10.1002/ajh.21367 126 
13.  Turba UC, Bozlar U, Simsek S. Catheter-directed thrombolysis of acute lower extremity 127 
arterial thrombosis in a patient with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv. 128 
2007;70(7):1046-1050. doi:10.1002/ccd.21304 129 
14.  Jang IK, Brown DFM, Giugliano RP, et al. A multicenter, randomized study of argatroban 130 
versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: 131 
Myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol. 1999;33(7):1879-1885. 132 
doi:10.1016/S0735-1097(99)00107-2 133 
15.  Barreto AD, Alexandrov A V., Lyden P, et al. The Argatroban and tissue-type plasminogen 134 







This article is protected by copyright. All rights reserved. 
 
















































































































































































































N/A 0.9 48 
 140 
 141 
 142 
